Citigroup analyst Alexander Hacking maintains Warrior Met Coal (NYSE:HCC) with a Neutral and raises the price target from $35 to $40.
Nkarta To Present NKX019 Phase 1 Dose Escalation Data At European Hematology Association 2023 Congress And 17th International Conference On Malignant Lymphoma
Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will present preliminary data from its Phase 1 dose escalation clinical trial of
